Janus Henderson Investors US’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Janus Henderson Investors US’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$19.6M	Buy	+359,675	New	+$17.7M	0.02%	612

Other funds holding BIVV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Janus Henderson Investors US's BIVV Position: Q1 2017 in Review

Janus Henderson Investors US opened a new position in Bioverativ Inc. Common Stock (BIVV) in Q1 2017: 359,675 shares worth $19.6M. The stake represents 0.02% of the portfolio and ranks #612 among its holdings.

467 funds tracked by Wall St. Rank hold BIVV as of Q1 2017.

Janus Henderson Investors US held 359,675 shares of Bioverativ Inc. Common Stock worth $19.6M as of Q1 2017.
Bioverativ Inc. Common Stock was a new Janus Henderson Investors US position in Q1 2017.
Bioverativ Inc. Common Stock made up 0.02% of Janus Henderson Investors US's portfolio in Q1 2017, its #612 holding.
467 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2017.

Based on Janus Henderson Investors US's 13F filing for Q1 2017, filed 16 May 2017.